Accelerating the development of innovative stem-cell therapies for clinical applications
In January of 2012, Max-Planck-Gesellschaft (MPG) and UNIST signed a partnership agreement that involves creating a joint laboratory. The two institutions have promised to combine their expertise in the field of stem cell research.
This partnership between MPG and UNIST will be now officially extended until December, 2016. This extended partnership will create synergic effects that will be mutually beneficial.
Located on the UNIST campus, this joint Max-Plankck-UNIST Laboratory for Molecular Biomedince Laboratory (MBL) aims to develop innovative cell therapeutic methods for clinical applications and possible solutions for degenerative and currently incurable disease.
In fact, researchers of the Max Planck Institute (MPI) for Molecular Biomedicine in Munster, along with MBL at UNIST have been making important advances in the development of patient-specific stem cells that is free of ethical issues and immunorejection.
“We are excited to extend our partnership with MPG. Together, we hope to accelerate our joint development of innovative cell therapeutic methods for clinical applications and possible solutions for degenerative and currently incurable disease,” said Prof. Jeong Beom Kim, Managing Director of MBL.
Max Planck Gesellschaft (MPG) is a research institute which has produced the largest number of Nobel Prize winners worldwide. The organization has produced 33 Nobel Prize winners including 16 winners from the former Kaiser-Wilhelm Gesellschaft, the research group in the field of basic science which operates Germany-based institutions in more than 80 countries around the world.